Andrea C Lo1,2, Vanessa Samuel3, Ben Chen3, Kerry J Savage3,4,5, Ciara Freeman3,4,5, Karen Goddard6,3. 1. Department of Radiation Oncology, British Columbia (BC) Cancer, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. Andrea.Lo@bccancer.bc.ca. 2. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Andrea.Lo@bccancer.bc.ca. 3. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 4. Centre of Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada. 5. Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada. 6. Department of Radiation Oncology, British Columbia (BC) Cancer, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
Abstract
PURPOSE: The study objective was to assess the discussion of late effects (LEs) and screening recommendations (SRs) for adolescent and young adults (AYAs) treated for lymphoma. METHODS: A retrospective study was conducted on AYA lymphoma survivors aged 15-24 years at diagnosis who received radiation therapy (RT) ± chemotherapy between 1984 and 2010 at any of the six British Columbia (BC) Cancer treatment centers across the province. Charts were reviewed to evaluate discussion of LEs and SRs. Susceptibility to specific LEs was determined by reviewing treatment details. RESULTS: Of 305 patients, 212 (70%) had documented discussion of at least one specific LE, 39 (13%) had non-specific documentation only, and 54 (18%) had no documented discussion of LEs. Accounting only for patients susceptible to each LEs, the most frequently discussed LEs was radiation-induced (RI) neoplasm (42%), and the least frequently discussed LEs was carotid artery stenosis (0.4%). The most common SRs discussed in susceptible patients was for RI breast cancer (43%). Of patients discharged between 1985 and 1999 vs 2000 and 2014, LEs were discussed in 63 vs 93% (P < 0.0005), and SRs were discussed in 30 vs 65%, respectively (P < 0.0005). Older age at discharge, presence of a discharge note, and occurrence of a discharge appointment were associated with increased discussion of SRs. CONCLUSIONS: Most survivors of AYA lymphoma received some discussion of LEs and SRs, but each relevant LEs and SRs was discussed in only a minority of susceptible patients. IMPLICATIONS FOR CANCER SURVIVORS: Survivors of AYA lymphoma and their primary care professionals may not be appropriately informed of health risks and how to screen for them.
PURPOSE: The study objective was to assess the discussion of late effects (LEs) and screening recommendations (SRs) for adolescent and young adults (AYAs) treated for lymphoma. METHODS: A retrospective study was conducted on AYA lymphoma survivors aged 15-24 years at diagnosis who received radiation therapy (RT) ± chemotherapy between 1984 and 2010 at any of the six British Columbia (BC) Cancer treatment centers across the province. Charts were reviewed to evaluate discussion of LEs and SRs. Susceptibility to specific LEs was determined by reviewing treatment details. RESULTS: Of 305 patients, 212 (70%) had documented discussion of at least one specific LE, 39 (13%) had non-specific documentation only, and 54 (18%) had no documented discussion of LEs. Accounting only for patients susceptible to each LEs, the most frequently discussed LEs was radiation-induced (RI) neoplasm (42%), and the least frequently discussed LEs was carotid artery stenosis (0.4%). The most common SRs discussed in susceptible patients was for RI breast cancer (43%). Of patients discharged between 1985 and 1999 vs 2000 and 2014, LEs were discussed in 63 vs 93% (P < 0.0005), and SRs were discussed in 30 vs 65%, respectively (P < 0.0005). Older age at discharge, presence of a discharge note, and occurrence of a discharge appointment were associated with increased discussion of SRs. CONCLUSIONS: Most survivors of AYA lymphoma received some discussion of LEs and SRs, but each relevant LEs and SRs was discussed in only a minority of susceptible patients. IMPLICATIONS FOR CANCER SURVIVORS: Survivors of AYA lymphoma and their primary care professionals may not be appropriately informed of health risks and how to screen for them.
Entities:
Keywords:
Adolescent and young adult; Documentation; Late effects; Lymphoma; Radiation therapy; Radiotherapy
Authors: Michael Schaapveld; Berthe M P Aleman; Anna M van Eggermond; Cécile P M Janus; Augustinus D G Krol; Richard W M van der Maazen; Judith Roesink; John M M Raemaekers; Jan Paul de Boer; Josée M Zijlstra; Gustaaf W van Imhoff; Eefke J Petersen; Philip M P Poortmans; Max Beijert; Marnix L Lybeert; Ina Mulder; Otto Visser; Marieke W J Louwman; Inge M Krul; Pieternella J Lugtenburg; Flora E van Leeuwen Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245
Authors: Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Marie L De Bruin; Mars B van 't Veer; Margreet H A Baaijens; Jan Paul de Boer; Augustinus A M Hart; Willem J Klokman; Marianne A Kuenen; Gabey M Ouwens; Harry Bartelink; Flora E van Leeuwen Journal: Blood Date: 2006-11-21 Impact factor: 22.113
Authors: Erin E Hahn; Yi-Lin Wu; Corrine E Munoz-Plaza; Jazmine Garcia Delgadillo; Robert M Cooper; Chun R Chao Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Sharyl J Nass; Lynda K Beaupin; Wendy Demark-Wahnefried; Karen Fasciano; Patricia A Ganz; Brandon Hayes-Lattin; Melissa M Hudson; Brenda Nevidjon; Kevin C Oeffinger; Ruth Rechis; Lisa C Richardson; Nita L Seibel; Ashley W Smith Journal: Oncologist Date: 2015-01-07
Authors: Mary L McBride; Paul C Rogers; Sam B Sheps; Victor Glickman; Anne-Marie Broemeling; Karen Goddard; Joan Hu; Maria Lorenzi; Stuart Peacock; Sheila Pritchard; Shahrad Rod Rassekh; Linda Siegel; John J Spinelli; Paulos Teckle; Lijing Xie Journal: Pediatr Blood Cancer Date: 2010-08 Impact factor: 3.167
Authors: Frederika A van Nimwegen; Michael Schaapveld; Cécile P M Janus; Augustinus D G Krol; Eefke J Petersen; John M M Raemaekers; Wouter E M Kok; Berthe M P Aleman; Flora E van Leeuwen Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: Paul Craig Nathan; Christopher Keller Daugherty; Kristen Elizabeth Wroblewski; Mackenzie Louise Kigin; Tom Vernon Stewart; Fay Jarmila Hlubocky; Eva Grunfeld; Marie Elisabeth Del Giudice; Leigh-Anne Evelyn Ward; James Mahlon Galliher; Kevin Charles Oeffinger; Tara Olive Henderson Journal: J Cancer Surviv Date: 2013-03-08 Impact factor: 4.442
Authors: Adam P Yan; Yan Chen; Tara O Henderson; Kevin C Oeffinger; Melissa M Hudson; Todd M Gibson; Joseph P Neglia; Wendy M Leisenring; Kirsten K Ness; Jennifer S Ford; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui; Paul C Nathan Journal: J Clin Oncol Date: 2020-03-06 Impact factor: 44.544